Assertio (ASRT) Stock Price, News & Analysis

Company Overview

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Key Stats

• Today's Range: $0.80 to $0.82
• 50-Day Range: $0.80 to $0.94
• 52-Week Range: $0.73 to $1.80
• Volume: 269,233 shs
• Average Volume: 315,717 shs
• Market Capitalization: $77.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.25
• Consensus Rating: Buy

Assertio Stock Analysis - MarketRank™

Assertio scored higher than 61% of companies evaluated by MarketBeat, and ranked 455th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Assertio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Assertio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Assertio are expected to grow in the coming year, from ($0.15) to $0.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Assertio is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Assertio is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Assertio has a PEG Ratio of 3.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Assertio has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.00% of the outstanding shares of Assertio have been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Assertio has recently decreased by 5.13%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Assertio does not currently pay a dividend.

Dividend Growth

Assertio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.00% of the outstanding shares of Assertio have been sold short.

Short Interest Ratio / Days to Cover

Assertio has a short interest ratio ("days to cover") of 7.6.

Change versus previous month

Short interest in Assertio has recently decreased by 5.13%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 1.46

News Sentiment

Assertio has a news sentiment score of 1.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Assertio this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for ASRT on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

Only 7 people have added Assertio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Assertio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Assertio is held by insiders.

Percentage Held by Institutions

48.96% of the stock of Assertio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ASRT Stock Analysis - Frequently Asked Questions

How have ASRT shares performed this year?

Assertio's stock was trading at $0.8711 at the start of the year. Since then, ASRT shares have decreased by 7.2% and is now trading at $0.8080.
View the best growth stocks for 2025 here.

How were Assertio's earnings last quarter?

Assertio Holdings, Inc. (NASDAQ:ASRT) released its quarterly earnings data on Monday, November, 11th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.02. The firm had revenue of $29.20 million for the quarter, compared to analysts' expectations of $29.29 million. Assertio had a negative net margin of 54.46% and a positive trailing twelve-month return on equity of 3.79%.

Who are Assertio's major shareholders?

Top institutional investors of Assertio include Nantahala Capital Management LLC (8.53%), Renaissance Technologies LLC (3.14%), Millennium Management LLC (1.15%) and Geode Capital Management LLC (1.15%). Insiders that own company stock include Daniel A Peisert, Heather L Mason, William Mckee, Jeff L Vacirca, Ajay Patel, Sam Schlessinger, Paul Schwichtenberg and Brendan P O'grady.
View institutional ownership trends.

How do I buy shares of Assertio?

Shares of ASRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Assertio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Assertio investors own include Plug Power (PLUG), FuelCell Energy (FCEL), Workhorse Group (WKHS), Fortress Biotech (FBIO), KALA BIO (KALA), Lipocine (LPCN) and Ovid Therapeutics (OVID).

Company Calendar

• Last Earnings: 11/11/2024
• Today: 2/21/2025
• Next Earnings (Estimated): 5/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ASRT
• CUSIP: N/A
• CIK: 1808665
• Web: www.assertiotx.com
• Phone: (224) 419-7106
• Fax: 510-744-8001
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.25
• High Stock Price Target: $4.00
• Low Stock Price Target: $2.75
• Potential Upside/Downside: +302.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.73)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 3.25
• Net Income: $-331,940,000.00
• Net Margins: -54.46%
• Pretax Margin: -33.94%
• Return on Equity: 3.79%
• Return on Assets: 1.81%

Debt

• Debt-to-Equity Ratio: 0.30
• Current Ratio: 2.01
• Quick Ratio: 1.57

Sales & Book Value

• Annual Sales: $125.76 million
• Price / Sales: 0.61
• Cash Flow: $0.72 per share
• Price / Cash Flow: 1.12
• Book Value: $1.46 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 95,478,000
• Free Float: 92,423,000
• Market Cap: $77.15 million
• Optionable: Optionable
• Beta: 0.76